Showing 201-210 of 235 results for "".
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conc…
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101. The retrospective study, conducted by a third-party statistician group, analyzed the correlation between response to CF101 and patients'…
- Innocutis Introduces Cold Sore Dissolvable Tablet to North American Markethttps://practicaldermatology.com/news/20140722-innocutis_introduces_cold_sore_dissolvable_tablet_to_north_american_market/2459160/Innocutis recently introduced Sitavig ®(ACYCLOVIR) 50mg Buccal Tablet to North American markets for the treatment of herpes labialis. Sitavig uses a proprietary delivery technology which consists of a tasteless and odorless tablet that sticks to the gum above the incisor tooth on the side of the li…
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline com…
- DNA to Host Annual Meeting in Orlando, May 1-4https://practicaldermatology.com/news/20140414-dna_to_host_annual_meeting_in_orlando_may_1-4/2459272/The Dermatology Nurses' Association (DNA) will host its 32nd Annual Convention at the Walt Disney World Swan and Dolphin in Orlando, Fla., May 1-4. The convention offers educational tracks in Pediatric Dermatology, Cosmetic Dermatology, Wound Management, Professional Practice, Medical Dermatology, …
- Syneron Receives FDA Clearance to Market the Ultrashape System for Fat Cell Destructionhttps://practicaldermatology.com/news/20140414-syneron_receives_fda_clearance_to_market_the_ultrashape_system_for_fat_cell_destruction/2459273/Syneron Medical Ltd. received FDA 510(k) clearance to market the UltraShape™ System for non-invasive reduction of abdominal circumference via fat cell destruction. The UltraShape System uses pulsed focused ultrasound energy that precisely targets subcutaneous fat, while keeping the surrounding tis…
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen, director of AboutSkin Dermatology and DermSurgery in Englewood and Lone Tree, Colorado and As…
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011…
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring systemic therapy”. Hemangeol is an oral solution specially devel…
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/The European Commission (EC) has approved the use of Xolair (omalizumab, Novartis) as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. The a…